VALOR hints at potential benefit of tofersen for SOD1 amyotrophic lateral sclerosis
Data from the open-label extension of the VALOR trial suggest that treatment with the intrathecally administered antisense oligonucleotide tofersen may modify the disease course of amyotrophic lateral sclerosis due to SOD1 mutations and lead to improvements in function.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Monoclonal antibodies disappoint in early Parkinson’s disease
Two monoclonal antibodies targeting aggregated α-synuclein have failed to improve clinical or imaging measures of Parkinson’s disease progression in the early-stage setting.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Ultrahigh-dose methylcobalamin shows promise for early-stage ALS
Treatment with ultrahigh-dose methylcobalamin may slow the functional decline of amyotrophic lateral sclerosis patients with early-stage disease and a moderate progression rate, indicate Japanese trial data published in JAMA Neurology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
